Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jun;22(6):754-755.
doi: 10.1634/theoncologist.2016-0469.

In Reply

Sunil Verma  1
Affiliations
Comment

In Reply

Sunil Verma. Oncologist. 2017 Jun.

Abstract

This letter describes preliminary results of a follow‐up study that was performed to assess the safety profile of palbociclib in premenopausal women with metastatic breast cancer.

PubMed Disclaimer

Comment on

References

    1. Altundag K. Safety analysis of premenopausal breast cancer patients in PALOMA-3 study: Is it worth mentioning? The Oncologist 2017;22:754. - PMC - PubMed
    1. Verma S, Bartlett CH, Schnell P et al. Palbociclib in combination with fulvestrant in women with hormone receptor‐positive/HER2‐negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo‐controlled, phase 3 study (PALOMA‐3). The Oncologist 2016;21:1165–1175. - PMC - PubMed
    1. Turner NC, Ro J, Andre F et al. Palbociclib in hormone‐receptor‐positive advanced breast cancer. N Engl J Med 2015;373:209–219. - PubMed
    1. Cristofanilli M, Turner NC, Bondarenko I et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone‐receptor‐positive, HER2‐negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA‐3): Final analysis of the multicentre, double‐blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425–439. - PubMed
    1. Loibl S, Turner NC, Ro J et al. Palbociclib in combination with fulvestrant in pre‐/perimenopausal women with metastatic breast cancer and prior progression on endocrine therapy: Results from PALOMA‐3. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2016; Chicago, IL.

LinkOut - more resources